Skip to main content

Morepen gets USFDA Approval for Fexofinadine (Allegra)

Pharma courses


pharma courses


pharma courses


pharma courses


Morepen gets USFDA Approval for Fexofinadine (Allegra)

Morepen Laboratories Limited has received USFDA approval for its anti-allergy drug Fexofinadine Hydrochloride that is market in India under the popular brand name Allegra, among others and is the block buster drug of the innovator company Sanofi Aventis, France. Fexofinadine is most widely used, second generation antihistamine drug for the treatment of allergy symptoms and hay fever.

The company has tied-up for regular supplies of Fexofinadine to one of its top US customers, with which the company has long standing relations lasting over two decades. The company has already supplied validation quantities and the regular commercial supplies would start after approval of validation batches. Fexofinadine is a very established anti-allergy drug with a market size of around 700MT and expected to give immediate impetus to company’s export business.

Morepen is the third largest exporters of this drug to the world and will move up in the ranks after this approval. The export of Fexofenadine to the highly regulated US market is expected to see multi-fold growth resulting in better profitability margins for the company. The company is having sufficient capacity to service the present demand and is also expanding capacities to become a leading player in the product in the coming years.

Fexofinadine is among top five leading products of the company and is the fourth anti-allergy drug in the Morepen’s product basket, in addition to Loratadine, Desloratadine and Montelukast. Morepen holds a leadership position in Loratadine group since last 20 years and was first to file for marketing permissions in USA markets. Fexofinadine is marketed primarily in two dosage forms 120mg and 180mg and is available to buy over the counter in many countries including USA, Australia, New Zealand, and certain countries around Europe. It is also used in combination with other anti-allergy drugs like Montelukast for which Morepen has got the largest manufacturing capacity in the world and is already approved in US market.

Mr. Sushil Suri, Chairman and Managing Director stated, “Approval of anti-allergy drug Fexofinadine (Allegra) by USFDA is an important milestone in the company’s therapeutic journey since it consolidates Morepen’s position in the anti-allergy market with already having USFDA approval for three lead products Loratadine, Desloratadine and Montelukast. It also cements our long-standing relations with our prime customers who have worked with us for two decades and shows their confidence in company’s product quality and delivery”

This approval of Fexofenadine is the 5th product approved by USFDA at Morepen facilities based at Baddi, in the Solan district of State of Himachal Pradesh. The company has got an excellent track record with the USFDA regulators and have never got any major/critical observations during its inspections. Morepen has strong portfolio of APIs with market size of over US$ 42 billion, which is going off patent over next 7-8 years and is building additional capacities in a multiphase USFDA expansion as demand for niche molecules and global customers remain stronger than ever and the market size, the company is looking to address, is US$ 42 billion compared to US$ 2 billion currently.

Morepen has been performing extremely well for last few years and had reported strong quarterly earnings with a stellar performance in Q2’FY22 with a growth of 70 per cent in its consolidated Profits (before tax) at Rs. 46.86 crores. Profit after tax (PAT) for the quarter has jumped 38 percent at Rs. 37.36 crores. The Quarterly revenues of the company at Rs. 398.17 crores have recorded an impressive growth of 17 percent during the current quarter as compared to quarterly revenues of Rs. 340.13 crores in Q2’FY21 where in it had registered a growth of 57 percent. This is sixth quarter in a row that the company continues the fast growth trajectory with remarkable gains in the bottom line.

Subscribe to PharmaTutor News Alerts by Email

<< Back to Pharma News

Search this website